Cargando…

A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia

Nintedanib (BIBF 1120), a potent multikinase inhibitor of VEGFR-1/-2/-3, FGFR-1/-2/-3 and PDGFR-α/-β, exerts growth inhibitory and pro-apoptotic effects in myeloid leukemic cells, especially when used in combination with cytarabine. This phase I study evaluated nintedanib in combination with low-dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Schliemann, Christoph, Gerss, Joachim, Wiebe, Stefanie, Mikesch, Jan-Henrik, Knoblauch, Nicola, Sauer, Tim, Angenendt, Linus, Kewitz, Tobias, Urban, Marc, Butterfass-Bahloul, Trude, Edemir, Sabine, Vehring, Kerstin, Müller-Tidow, Carsten, Berdel, Wolfgang E., Krug, Utz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055288/
https://www.ncbi.nlm.nih.gov/pubmed/27716819
http://dx.doi.org/10.1371/journal.pone.0164499
_version_ 1782458742309126144
author Schliemann, Christoph
Gerss, Joachim
Wiebe, Stefanie
Mikesch, Jan-Henrik
Knoblauch, Nicola
Sauer, Tim
Angenendt, Linus
Kewitz, Tobias
Urban, Marc
Butterfass-Bahloul, Trude
Edemir, Sabine
Vehring, Kerstin
Müller-Tidow, Carsten
Berdel, Wolfgang E.
Krug, Utz
author_facet Schliemann, Christoph
Gerss, Joachim
Wiebe, Stefanie
Mikesch, Jan-Henrik
Knoblauch, Nicola
Sauer, Tim
Angenendt, Linus
Kewitz, Tobias
Urban, Marc
Butterfass-Bahloul, Trude
Edemir, Sabine
Vehring, Kerstin
Müller-Tidow, Carsten
Berdel, Wolfgang E.
Krug, Utz
author_sort Schliemann, Christoph
collection PubMed
description Nintedanib (BIBF 1120), a potent multikinase inhibitor of VEGFR-1/-2/-3, FGFR-1/-2/-3 and PDGFR-α/-β, exerts growth inhibitory and pro-apoptotic effects in myeloid leukemic cells, especially when used in combination with cytarabine. This phase I study evaluated nintedanib in combination with low-dose cytarabine (LDAC) in elderly patients with untreated or relapsed/refractory acute myeloid leukemia (AML) ineligible for intensive chemotherapy in a 3+3 design. Nintedanib (dose levels 100, 150, and 200 mg orally twice daily) and LDAC (20 mg subcutaneous injection twice daily for 10 days) were administered in 28-day cycles. Dose-limiting toxicity (DLT) was defined as non-hematological severe adverse reaction CTC grade ≥ 4 with possible or definite relationship to nintedanib. Between April 2012 and October 2013, 13 patients (median age 73 [range: 62–86] years) were enrolled. One patient did not receive study medication and was replaced. Nine (69%) patients had relapsed or refractory disease and 6 (46%) patients had unfavorable cytogenetics. The most frequently reported treatment-related adverse events (AE) were gastrointestinal events. Twelve SAEs irrespective of relatedness were reported. Two SUSARs were observed, one fatal hypercalcemia and one fatal gastrointestinal infection. Two patients (17%) with relapsed AML achieved a complete remission (one CR, one CRi) and bone marrow blast reductions without fulfilling PR criteria were observed in 3 patients (25%). One-year overall survival was 33%. Nintedanib combined with LDAC shows an adequate safety profile and survival data are promising in a difficult-to-treat patient population. Continuation of this trial with a phase II recommended dose of 2 x 200 mg nintedanib in a randomized, placebo-controlled phase II study is planned. The trial is registered to EudraCT as 2011-001086-41. Trial Registration: ClinicalTrials.gov NCT01488344
format Online
Article
Text
id pubmed-5055288
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-50552882016-10-27 A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia Schliemann, Christoph Gerss, Joachim Wiebe, Stefanie Mikesch, Jan-Henrik Knoblauch, Nicola Sauer, Tim Angenendt, Linus Kewitz, Tobias Urban, Marc Butterfass-Bahloul, Trude Edemir, Sabine Vehring, Kerstin Müller-Tidow, Carsten Berdel, Wolfgang E. Krug, Utz PLoS One Research Article Nintedanib (BIBF 1120), a potent multikinase inhibitor of VEGFR-1/-2/-3, FGFR-1/-2/-3 and PDGFR-α/-β, exerts growth inhibitory and pro-apoptotic effects in myeloid leukemic cells, especially when used in combination with cytarabine. This phase I study evaluated nintedanib in combination with low-dose cytarabine (LDAC) in elderly patients with untreated or relapsed/refractory acute myeloid leukemia (AML) ineligible for intensive chemotherapy in a 3+3 design. Nintedanib (dose levels 100, 150, and 200 mg orally twice daily) and LDAC (20 mg subcutaneous injection twice daily for 10 days) were administered in 28-day cycles. Dose-limiting toxicity (DLT) was defined as non-hematological severe adverse reaction CTC grade ≥ 4 with possible or definite relationship to nintedanib. Between April 2012 and October 2013, 13 patients (median age 73 [range: 62–86] years) were enrolled. One patient did not receive study medication and was replaced. Nine (69%) patients had relapsed or refractory disease and 6 (46%) patients had unfavorable cytogenetics. The most frequently reported treatment-related adverse events (AE) were gastrointestinal events. Twelve SAEs irrespective of relatedness were reported. Two SUSARs were observed, one fatal hypercalcemia and one fatal gastrointestinal infection. Two patients (17%) with relapsed AML achieved a complete remission (one CR, one CRi) and bone marrow blast reductions without fulfilling PR criteria were observed in 3 patients (25%). One-year overall survival was 33%. Nintedanib combined with LDAC shows an adequate safety profile and survival data are promising in a difficult-to-treat patient population. Continuation of this trial with a phase II recommended dose of 2 x 200 mg nintedanib in a randomized, placebo-controlled phase II study is planned. The trial is registered to EudraCT as 2011-001086-41. Trial Registration: ClinicalTrials.gov NCT01488344 Public Library of Science 2016-10-07 /pmc/articles/PMC5055288/ /pubmed/27716819 http://dx.doi.org/10.1371/journal.pone.0164499 Text en © 2016 Schliemann et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Schliemann, Christoph
Gerss, Joachim
Wiebe, Stefanie
Mikesch, Jan-Henrik
Knoblauch, Nicola
Sauer, Tim
Angenendt, Linus
Kewitz, Tobias
Urban, Marc
Butterfass-Bahloul, Trude
Edemir, Sabine
Vehring, Kerstin
Müller-Tidow, Carsten
Berdel, Wolfgang E.
Krug, Utz
A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
title A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
title_full A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
title_fullStr A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
title_full_unstemmed A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
title_short A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
title_sort phase i dose escalation study of the triple angiokinase inhibitor nintedanib combined with low-dose cytarabine in elderly patients with acute myeloid leukemia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055288/
https://www.ncbi.nlm.nih.gov/pubmed/27716819
http://dx.doi.org/10.1371/journal.pone.0164499
work_keys_str_mv AT schliemannchristoph aphaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT gerssjoachim aphaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT wiebestefanie aphaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT mikeschjanhenrik aphaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT knoblauchnicola aphaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT sauertim aphaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT angenendtlinus aphaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT kewitztobias aphaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT urbanmarc aphaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT butterfassbahloultrude aphaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT edemirsabine aphaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT vehringkerstin aphaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT mullertidowcarsten aphaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT berdelwolfgange aphaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT krugutz aphaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT schliemannchristoph phaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT gerssjoachim phaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT wiebestefanie phaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT mikeschjanhenrik phaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT knoblauchnicola phaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT sauertim phaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT angenendtlinus phaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT kewitztobias phaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT urbanmarc phaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT butterfassbahloultrude phaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT edemirsabine phaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT vehringkerstin phaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT mullertidowcarsten phaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT berdelwolfgange phaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia
AT krugutz phaseidoseescalationstudyofthetripleangiokinaseinhibitornintedanibcombinedwithlowdosecytarabineinelderlypatientswithacutemyeloidleukemia